The move follows similar initiatives by players like Syngene, Laurus Labs, and Aragen. Industry analysts see Bharat Biotech’s ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...

A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a ...

Dr. Katz's research shows how important it is for all breast cancer survivors to have access to genetic testing services, ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Imagine if you can get your $100 million athlete back before the end of the season,” said Dr. Paul Liu, executive chairman of Pax Therapeutics.

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

Mother Daphne Graskewicz-Prado of Southern Illinois told Newsweek: “I wasn’t going to accept the terminal diagnosis.” ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...